1. Comparison of Multimaterial Decomposition Fat Fraction with DECT and Proton Density Fat Fraction with IDEAL IQ MRI for Quantification of Liver Steatosis in a Population Exposed to Chemotherapy. Issue 2 (19th April 2021) Authors: Corrias, Giuseppe; Erta, Marco; Sini, Marcello; Sardu, Claudia; Saba, Luca; Mahmood, Usman; Castellanos, Sandra Huicochea; Bates, David; Mondanelli, Nicola; Thomsen, Brian; Carollo, Gabriella; Sawan, Peter; Mannelli, Lorenzo Journal: Dose-response Issue: Volume 19:Issue 2(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Dual energy computed tomography analysis in cancer patients: What factors affect iodine concentration in contrast enhanced studies?. Issue 120 (November 2019) Authors: Corrias, Giuseppe; Sawan, Peter; Mahmood, Usman; Zheng, Junting; Capanu, Marinela; Salvatore, Marco; Spinato, Giacomo; Saba, Luca; Mannelli, Lorenzo Journal: European journal of radiology Issue: Issue 120(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Dual Energy Computed Tomography and Contrast Dose. Issue 4 (5th December 2021) Authors: Corrias, Giuseppe; Mahmood, Usman; Pizzi, Aldo; Sawan, Peter; Saba, Luca; Spinato, Giacomo; Mondanelli, Nicola; Mannelli, Lorenzo Journal: Dose-response Issue: Volume 19:Issue 4(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status. Issue 2 (4th August 2020) Authors: Alessi, Joao V; Ricciuti, Biagio; Jiménez-Aguilar, Elizabeth; Hong, Fangxin; Wei, Zihan; Nishino, Mizuki; Plodkowski, Andrew J; Sawan, Peter; Luo, Jia; Rizvi, Hira; Carter, Brett W; Heymach, John V; Altan, Mehmet; Hellmann, Matthew; Awad, Mark Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status. Issue 2 (4th August 2020) Authors: Alessi, Joao V; Ricciuti, Biagio; Jiménez-Aguilar, Elizabeth; Hong, Fangxin; Wei, Zihan; Nishino, Mizuki; Plodkowski, Andrew J; Sawan, Peter; Luo, Jia; Rizvi, Hira; Carter, Brett W; Heymach, John V; Altan, Mehmet; Hellmann, Matthew; Awad, Mark Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status. Issue 2 (4th August 2020) Authors: Alessi, Joao V; Ricciuti, Biagio; Jiménez-Aguilar, Elizabeth; Hong, Fangxin; Wei, Zihan; Nishino, Mizuki; Plodkowski, Andrew J; Sawan, Peter; Luo, Jia; Rizvi, Hira; Carter, Brett W; Heymach, John V; Altan, Mehmet; Hellmann, Matthew; Awad, Mark Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status. Issue 2 (4th August 2020) Authors: Alessi, Joao V; Ricciuti, Biagio; Jiménez-Aguilar, Elizabeth; Hong, Fangxin; Wei, Zihan; Nishino, Mizuki; Plodkowski, Andrew J; Sawan, Peter; Luo, Jia; Rizvi, Hira; Carter, Brett W; Heymach, John V; Altan, Mehmet; Hellmann, Matthew; Awad, Mark Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status. Issue 2 (4th August 2020) Authors: Alessi, Joao V; Ricciuti, Biagio; Jiménez-Aguilar, Elizabeth; Hong, Fangxin; Wei, Zihan; Nishino, Mizuki; Plodkowski, Andrew J; Sawan, Peter; Luo, Jia; Rizvi, Hira; Carter, Brett W; Heymach, John V; Altan, Mehmet; Hellmann, Matthew; Awad, Mark Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status. Issue 2 (4th August 2020) Authors: Alessi, Joao V; Ricciuti, Biagio; Jiménez-Aguilar, Elizabeth; Hong, Fangxin; Wei, Zihan; Nishino, Mizuki; Plodkowski, Andrew J; Sawan, Peter; Luo, Jia; Rizvi, Hira; Carter, Brett W; Heymach, John V; Altan, Mehmet; Hellmann, Matthew; Awad, Mark Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status. Issue 2 (4th August 2020) Authors: Alessi, Joao V; Ricciuti, Biagio; Jiménez-Aguilar, Elizabeth; Hong, Fangxin; Wei, Zihan; Nishino, Mizuki; Plodkowski, Andrew J; Sawan, Peter; Luo, Jia; Rizvi, Hira; Carter, Brett W; Heymach, John V; Altan, Mehmet; Hellmann, Matthew; Awad, Mark Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗